BerGenBio

BerGenBio ASA: New share capital registered

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange

announcement by BerGenBio ASA (the "Company") on 23 May 2024 regarding the

Company's annual general meeting resolving to increase the Company's share

capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of

NOK 0.10 to ensure that the Company's total number of outstanding shares are

divisible by 100 and thereby facilitate for the reverse share split in the

Company resolved at the same general meeting.

The share capital increases pertaining to the new shares is now registered with

the Norwegian Register of Business Enterprises. After this, the Company's new

registered share capital is NOK 390,871,160 divided into 3,908,711,600 shares,

each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo

Rule Book II and is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal